{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T20:08:30Z","timestamp":1793045310459,"version":"4.5.0"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,2,6]],"date-time":"2021-02-06T00:00:00Z","timestamp":1612569600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2021,2,6]],"date-time":"2021-02-06T00:00:00Z","timestamp":1612569600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Jiangxi Educational Department Foundation of China","award":["GJJ170628"],"award-info":[{"award-number":["GJJ170628"]}]},{"name":"Nature Science Foundation of Jiangxi Province","award":["20181BAB205024"],"award-info":[{"award-number":["20181BAB205024"]}]},{"name":"Nature Science Foundation of Jiangxi Province","award":["20202BABL206161"],"award-info":[{"award-number":["20202BABL206161"]}]},{"name":"Technology Program of Jiangxi Administration of Traditional Chinese Medicine","award":["2019A178"],"award-info":[{"award-number":["2019A178"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Side population (SP) cells, which have similar features to those of cancer stem cells, show resistance to dexamethasone (Dex) treatment. Thus, new drugs that can be used in combination with Dex to reduce the population of SP cells in multiple myeloma (MM) are required. Diallyl thiosulfinate (DATS, allicin), a natural organosulfur compound derived from garlic, has been shown to inhibit the proliferation of SP cells in MM cell lines. Therefore, we investigated the effect of a combination of DATS and Dex (DAT\u2009+\u2009Dex) on MM SP cells.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>SP cells were sorted from MM RPMI-8226 and NCI-H929 cell lines using Hoechst 33342-labeled fluorescence-activated cell sorting. The growth of SP cells was evaluated using the cell counting kit-8 assay. Cell cycle and apoptosis assays were conducted using a BD Calibur flow cytometer. miRNA expression was measured using quantitative reverse transcription-polymerase chain reaction. Phosphoinositide 3-kinase (PI3K), phosphorylated AKT (p-AKT), AKT, p-mechanistic target of rapamycin (mTOR), and mTOR levels were measured using western blot analysis.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Our results showed that the combination of DATS+Dex inhibited sphere formation<jats:bold>,<\/jats:bold> colony formation, and proliferation of MM SP cells by inducing apoptosis and cell cycle arrest in the G1\/S phase. In addition, the combination of DATS+Dex promoted miR-127-3p expression and inhibited PI3K, p-AKT, and p-mTOR expression in SP cells. Knockdown of miR-127-3p expression weakened the effect of DATS+Dex on cell proliferation, colony formation, apoptosis, and cell cycle of MM SP cells. Additionally, knockdown of miR-127-3p activated the PI3K\/AKT\/mTOR signaling pathway in MM SP cells cotreated with DATS+Dex.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>We demonstrated that cotreatment with DATS+Dex reduced cell proliferation, promoted apoptosis, and caused cell cycle arrest of MM SP cells by promoting miR-127-3p expression and deactivating the PI3K\/AKT\/mTOR signaling pathway.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12885-021-07833-5","type":"journal-article","created":{"date-parts":[[2021,2,8]],"date-time":"2021-02-08T18:37:11Z","timestamp":1612809431000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":27,"title":["Diallyl thiosulfinate enhanced the anti-cancer activity of dexamethasone in the side population cells of multiple myeloma by promoting miR-127-3p and deactivating the PI3K\/AKT signaling pathway"],"prefix":"10.1186","volume":"21","author":[{"given":"Wenfeng","family":"He","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yonghui","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongliang","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoping","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9823-8284","authenticated-orcid":false,"given":"Junquan","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,2,6]]},"reference":[{"issue":"Suppl 1","key":"7833_CR1","doi-asserted-by":"publisher","first-page":"S5","DOI":"10.1016\/S0268-960X(10)70003-5","volume":"24","author":"A Mahindra","year":"2010","unstructured":"Mahindra A, Hideshima T, Anderson KC. Multiple myeloma: biology of the disease. Blood Rev. 2010;24(Suppl 1):S5\u201311.","journal-title":"Blood Rev"},{"issue":"1","key":"7833_CR2","doi-asserted-by":"publisher","first-page":"42","DOI":"10.2174\/18715273113126660189","volume":"13","author":"SM Fayaz","year":"2014","unstructured":"Fayaz SM, Suvanish Kumar VS, Rajanikant GK. Necroptosis: who knew there were so many interesting ways to die? CNS Neurol Disord Drug Targets. 2014;13(1):42\u201351.","journal-title":"CNS Neurol Disord Drug Targets"},{"issue":"4","key":"7833_CR3","doi-asserted-by":"publisher","first-page":"1797","DOI":"10.1084\/jem.183.4.1797","volume":"183","author":"MA Goodell","year":"1996","unstructured":"Goodell MA, Brose K, Paradis G, Conner AS, Mulligan RC. Isolation and functional properties of murine hematopoietic stem cells that are replicating in vivo. J Exp Med. 1996;183(4):1797\u2013806.","journal-title":"J Exp Med"},{"issue":"4","key":"7833_CR4","first-page":"1250","volume":"25","author":"L Wang","year":"2017","unstructured":"Wang L. Li Y: [research advances of side population cells in multiple myeloma -review]. Zhongguo shi yan xue ye xue za zhi. 2017;25(4):1250\u20134.","journal-title":"Zhongguo shi yan xue ye xue za zhi"},{"issue":"9686","key":"7833_CR5","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1016\/S0140-6736(09)60221-X","volume":"374","author":"MS Raab","year":"2009","unstructured":"Raab MS, Podar K, Breitkreutz I, Richardson PG, Anderson KC. Multiple myeloma. Lancet. 2009;374(9686):324\u201339.","journal-title":"Lancet"},{"key":"7833_CR6","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.leukres.2016.10.010","volume":"51","author":"W Yan","year":"2016","unstructured":"Yan W, Du J, Du Y, Pu H, Liu S, He J, Zhang J, Hou J. Fenretinide targets the side population in myeloma cell line NCI-H929 and potentiates the efficacy of antimyeloma with bortezomib and dexamethasone regimen. Leuk Res. 2016;51:32\u201340.","journal-title":"Leuk Res"},{"issue":"10","key":"7833_CR7","first-page":"1031","volume":"16","author":"P Mikaili","year":"2013","unstructured":"Mikaili P, Maadirad S, Moloudizargari M, Aghajanshakeri S, Sarahroodi S. Therapeutic uses and pharmacological properties of garlic, shallot, and their biologically active compounds. Iran J Basic Med Sci. 2013;16(10):1031\u201348.","journal-title":"Iran J Basic Med Sci"},{"issue":"2","key":"7833_CR8","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1111\/jcmm.12486","volume":"19","author":"KC Lai","year":"2015","unstructured":"Lai KC, Hsu SC, Yang JS, Yu CC, Lein JC, Chung JG. Diallyl trisulfide inhibits migration, invasion and angiogenesis of human colon cancer HT-29 cells and umbilical vein endothelial cells, and suppresses murine xenograft tumour growth. J Cell Mol Med. 2015;19(2):474\u201384.","journal-title":"J Cell Mol Med"},{"issue":"4","key":"7833_CR9","first-page":"1086","volume":"25","author":"JQ Zeng","year":"2017","unstructured":"Zeng JQ, Zheng YL, Liu B, Lian JP, Gong ZN. Mechanism of DATS inhibiting side population cell proliferation in multiple myeloma. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2017;25(4):1086\u201391.","journal-title":"Zhongguo Shi Yan Xue Ye Xue Za Zhi"},{"issue":"6","key":"7833_CR10","doi-asserted-by":"publisher","first-page":"3648","DOI":"10.3892\/or.2016.4722","volume":"35","author":"H Wang","year":"2016","unstructured":"Wang H, Sun N, Li X, Li K, Tian J, Li J. Diallyl trisulfide induces osteosarcoma cell apoptosis through reactive oxygen species-mediated downregulation of the PI3K\/Akt pathway. Oncol Rep. 2016;35(6):3648\u201358.","journal-title":"Oncol Rep"},{"issue":"1","key":"7833_CR11","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.etap.2013.11.002","volume":"37","author":"DY Shin","year":"2014","unstructured":"Shin DY, Kim GY, Hwang HJ, Kim WJ, Choi YH. Diallyl trisulfide-induced apoptosis of bladder cancer cells is caspase-dependent and regulated by PI3K\/Akt and JNK pathways. Environ Toxicol Pharmacol. 2014;37(1):74\u201383.","journal-title":"Environ Toxicol Pharmacol"},{"key":"7833_CR12","first-page":"1555","volume":"9","author":"NK Niu","year":"2015","unstructured":"Niu NK, Wang ZL, Pan ST, Ding HQ, Au GH, He ZX, Zhou ZW, Xiao G, Yang YX, Zhang X, et al. Pro-apoptotic and pro-autophagic effects of the Aurora kinase a inhibitor alisertib (MLN8237) on human osteosarcoma U-2 OS and MG-63 cells through the activation of mitochondria-mediated pathway and inhibition of p38 MAPK\/PI3K\/Akt\/mTOR signaling pathway. Drug Design Dev Therapy. 2015;9:1555\u201384.","journal-title":"Drug Design Dev Therapy"},{"issue":"33","key":"7833_CR13","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000016711","volume":"98","author":"P Xu","year":"2019","unstructured":"Xu P, Xia T, Ling Y, Chen B. MiRNAs with prognostic significance in multiple myeloma: a systemic review and meta-analysis. Medicine. 2019;98(33):e16711.","journal-title":"Medicine"},{"issue":"8","key":"7833_CR14","doi-asserted-by":"publisher","first-page":"e0221199","DOI":"10.1371\/journal.pone.0221199","volume":"14","author":"YH Huang","year":"2019","unstructured":"Huang YH, Chen ST, Liu FH, Hsieh SH, Lin CH, Liou MJ, Wang CC, Huang CH, Liu GH, Lin JR, et al. The efficacy and safety of concentrated herbal extract granules, YH1, as an add-on medication in poorly controlled type 2 diabetes: a randomized, double-blind, placebo-controlled pilot trial. PLoS One. 2019;14(8):e0221199.","journal-title":"PLoS One"},{"issue":"4","key":"7833_CR15","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1080\/15548627.2019.1635380","volume":"16","author":"H Wu","year":"2020","unstructured":"Wu H, Liu C, Yang Q, Xin C, Du J, Sun F, Zhou L. MIR145-3p promotes autophagy and enhances bortezomib sensitivity in multiple myeloma by targeting HDAC4. Autophagy. 2020;16(4):683\u201397.","journal-title":"Autophagy."},{"issue":"14","key":"7833_CR16","doi-asserted-by":"publisher","first-page":"1660","DOI":"10.1080\/15384101.2019.1632138","volume":"18","author":"X Yuan","year":"2019","unstructured":"Yuan X, Ma R, Yang S, Jiang L, Wang Z, Zhu Z, Li H. miR-520g and miR-520h overcome bortezomib resistance in multiple myeloma via suppressing APE1. Cell Cycle (Georgetown, Tex). 2019;18(14):1660\u20139.","journal-title":"Cell Cycle (Georgetown, Tex)"},{"issue":"17","key":"7833_CR17","doi-asserted-by":"publisher","first-page":"14993","DOI":"10.18632\/oncotarget.3802","volume":"6","author":"J Du","year":"2015","unstructured":"Du J, Liu S, He J, Liu X, Qu Y, Yan W, Fan J, Li R, Xi H, Fu W, et al. MicroRNA-451 regulates stemness of side population cells via PI3K\/Akt\/mTOR signaling pathway in multiple myeloma. Oncotarget. 2015;6(17):14993\u20135007.","journal-title":"Oncotarget"},{"key":"7833_CR18","volume-title":"Diallyl trisulfide inhibits proliferation and promotes apoptosis of side population cells in multiple myeloma cells","author":"J Zeng","year":"2017","unstructured":"Zeng J, Liu T, Zheng Y, Liu B, Fang M, Long S, Chen Y. Diallyl trisulfide inhibits proliferation and promotes apoptosis of side population cells in multiple myeloma cells, vol. 10; 2017."},{"issue":"7","key":"7833_CR19","doi-asserted-by":"publisher","first-page":"106","DOI":"10.4103\/0973-7847.65321","volume":"4","author":"BB Petrovska","year":"2010","unstructured":"Petrovska BB, Cekovska S. Extracts from the history and medical properties of garlic. Pharmacogn Rev. 2010;4(7):106\u201310.","journal-title":"Pharmacogn Rev"},{"issue":"2","key":"7833_CR20","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/S1995-7645(14)60304-7","volume":"8","author":"XY Gao","year":"2015","unstructured":"Gao XY, Geng XJ, Zhai WL, Zhang XW, Wei Y, Hou GJ. Effect of combined treatment with cyclophosphamidum and allicin on neuroblastoma-bearing mice. Asian Pac J Trop Med. 2015;8(2):137\u201341.","journal-title":"Asian Pac J Trop Med"},{"issue":"12","key":"7833_CR21","doi-asserted-by":"publisher","first-page":"6579","DOI":"10.1007\/s11033-013-2766-1","volume":"40","author":"CJ Wang","year":"2013","unstructured":"Wang CJ, Wang C, Han J, Wang YK, Tang L, Shen DW, Zhao Y, Xu RH, Zhang H. Effect of combined treatment with recombinant interleukin-2 and allicin on pancreatic cancer. Mol Biol Rep. 2013;40(12):6579\u201385.","journal-title":"Mol Biol Rep"},{"issue":"7","key":"7833_CR22","doi-asserted-by":"publisher","first-page":"14171","DOI":"10.3390\/ijms140714171","volume":"14","author":"LH Guo","year":"2013","unstructured":"Guo LH, Li H, Wang F, Yu J, He JS. The tumor suppressor roles of miR-433 and miR-127 in gastric Cancer. Int J Mol Sci. 2013;14(7):14171\u201384.","journal-title":"Int J Mol Sci"},{"issue":"3","key":"7833_CR23","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1002\/1873-3468.13624","volume":"594","author":"J Fan","year":"2020","unstructured":"Fan J, Du W, Zhang H, Wang Y, Li K, Meng Y, Wang J. Transcriptional downregulation of miR-127-3p by CTCF promotes prostate cancer bone metastasis by targeting PSMB5. FEBS Lett. 2020;594(3):466\u201376.","journal-title":"FEBS Lett."},{"key":"7833_CR24","doi-asserted-by":"publisher","unstructured":"Liu X, Meng Z, Xing Y, Zhong Q, Zhang X, Qu J. MiR-127 inhibits ovarian cancer migration and invasion by up-regulating ITGA6. Minerva Med. 2019. https:\/\/doi.org\/10.23736\/S0026-4806.19.06237-2. Online ahead of print.","DOI":"10.23736\/S0026-4806.19.06237-2"},{"issue":"7","key":"7833_CR25","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1038\/nrc839","volume":"2","author":"I Vivanco","year":"2002","unstructured":"Vivanco I, Sawyers CL. The phosphatidylinositol 3-kinase AKT pathway in human cancer. Nat Rev Cancer. 2002;2(7):489\u2013501.","journal-title":"Nat Rev Cancer"},{"issue":"9","key":"7833_CR26","doi-asserted-by":"publisher","first-page":"2853","DOI":"10.1182\/blood.V98.9.2853","volume":"98","author":"J Hsu","year":"2001","unstructured":"Hsu J, Shi Y, Krajewski S, Renner S, Fisher M, Reed JC, Franke TF, Lichtenstein A. The AKT kinase is activated in multiple myeloma tumor cells. Blood. 2001;98(9):2853\u20135.","journal-title":"Blood"},{"issue":"43","key":"7833_CR27","doi-asserted-by":"publisher","first-page":"6587","DOI":"10.1038\/sj.onc.1205923","volume":"21","author":"F Pene","year":"2002","unstructured":"Pene F, Claessens YE, Muller O, Viguie F, Mayeux P, Dreyfus F, Lacombe C, Bouscary D. Role of the phosphatidylinositol 3-kinase\/Akt and mTOR\/P70S6-kinase pathways in the proliferation and apoptosis in multiple myeloma. Oncogene. 2002;21(43):6587\u201397.","journal-title":"Oncogene"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-021-07833-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12885-021-07833-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-021-07833-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,8]],"date-time":"2021-02-08T18:37:47Z","timestamp":1612809467000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-021-07833-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,6]]},"references-count":27,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["7833"],"URL":"https:\/\/doi.org\/10.1186\/s12885-021-07833-5","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,6]]},"assertion":[{"value":"21 June 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 December 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 February 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"125"}}